AN2 Therapeutics (ANTX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$8.2M

Net income growth (year over year)

−26.66%

Net margin

—

Return on equity

−50.12%

EPS (trailing twelve months)

−$1.05

Book value per share

$2.09

P/E (trailing twelve months)

—

Price to book

1.78

Debt to assets

7.05%

Payout ratio

—

Dividend yield

—

Company profile

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

• How do I buy stock in AN2 Therapeutics (ANTX)?

  ANTX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.